Our results indicated that the removal of CD8+ T cells or both CD4+ and CD8+ T cells entirely negated the tumour regression triggered by the combination therapy, while the elimination of only CD4+ T cells did not have a notable effect (Figure 2F). The gene discussed is CD8A; the disease is neoplasm.